This article is more than 5 years old. Information may no longer be current.
Aerie, DSM enter collaboration agreement
Aerie Pharmaceuticals and DSM have entered into a collaborative research, development and license agreement, according to an Aerie press release.
The agreement includes an option to license DSM’s bioerodible polymer implant technology in order to deliver Aerie’s compounds to treat retinal diseases, the release said.
AR-13154, Aerie’s preclinical product candidate, has been shown to decrease lesion size in a preclinical model of wet age-related macular degeneration. DSM’s injectable, thin-fiber technology, which uses polyesteramide polymers, demonstrated early success with Aerie compounds, showing linear sustained elution rates over several months.
“A key to unlocking the potential of AR-13154 and related Aerie-owned compounds for the treatment of retinal diseases is the identification of the appropriate technology to achieve longer-term sustained delivery of our small molecules to the back of the eye,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We are hopeful that DSM’s [polyesteramide polymers] technology may prove to be that technology.”
Financial terms of the agreement were not disclosed.